ALN-VSP: Completed Phase I enrollment

Alnylam completed enrollment of over 40 patients in an open-label, dose-escalation Phase I trial evaluating 0.1-1.5 mg/kg IV ALN-VSP. The company developed ALN-VSP using Tekmira's stable nucleic acid-...